scholarly journals Li-Fraumeni syndrome: Adrenal cortical tumor in a newborn followed by a choroid plexus tumor

2018 ◽  
Vol 33 ◽  
pp. 58-61
Author(s):  
Jamie E. Anderson ◽  
Rebecca A. Stark
2017 ◽  
Vol 39 (8) ◽  
pp. e473-e475 ◽  
Author(s):  
Matthew McEvoy ◽  
Nathan Robison ◽  
Peter Manley ◽  
Torunn Yock ◽  
Kristine Konopka ◽  
...  

2005 ◽  
Vol 27 (1) ◽  
pp. 46-49 ◽  
Author(s):  
David S Dickens ◽  
Judith A Dothage ◽  
Richard L Heideman ◽  
Edgar T Ballard ◽  
Paul T Jubinsky

Neurosurgery ◽  
1993 ◽  
Vol 32 (1) ◽  
pp. 131-134 ◽  
Author(s):  
Hiroshi Yuasa ◽  
Sumitaka Tokito ◽  
Masayoshi Tokunaga

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Ofelia Cruz ◽  
Victoria Caloretti ◽  
Hector Salvador ◽  
Veronica Celis ◽  
Vicente Santa-Maria ◽  
...  

Abstract Background Li-Fraumeni Syndrome (LFS) is a cancer predisposition syndrome characterized by the early-onset of multiple primary cancers which can occur at different moments (metachronous onset) or, more rarely, coincidentally (synchronous onset). Here we describe a previously unreported patient with presentation of synchronous Wilms tumor and Choroid plexus papilloma, leading to the diagnosis of a Li-Fraumeni Syndrome (LFS). Case presentation A 6-year-old girl without previous complains presented with abdominal pain. Abdominal US and MRI showed a left renal tumor with subcapsular hematoma. Due to mild headaches, the diagnostic workup included a brain MRI that unexpectedly identified a large left parietal lobe tumor. Histopathological analysis determined the diagnosis of classic Wilms tumor and choroid-plexus papilloma (CPP), respectively. Both neoplasms showed intense nuclear p53 immunostaining associated with the pathogenic TP53 mutation c.844C > T (p.Arg282Trp). Our patient and her father shared the same heterozygous germline TP53 mutation, confirming the diagnosis of familiar Li-Fraumeni syndrome in the girl. The treatment was tailored to simultaneous tumor presentations. Conclusions LFS has been associated with Choroid plexus carcinoma (CPC), but rarely with CPP as in our patient. That suggests that it may be advisable to consider the possibility of analyzing TP53 mutation, not only in all patients with CPC, but also in some patients with CPP, especially when histological or clinical evidences point out to perform this study. The dissimilar presentation of LFS among our patient’s father, not having so far any neoplasia diagnosed, while her daughter presented precociously with two simultaneous different tumors, could be related to possible effects of modifier genes on the underlying mutant p53 genotype.


Author(s):  
A. F. Valiakhmetova ◽  
L. I. Papusha ◽  
L. A. Yasko ◽  
A. E. Druy ◽  
S. K. Gorelyshev ◽  
...  

Choroid plexus carcinoma (CPC) is a rare malignant tumor arising from the epithelium of the choroid plexus of the brain. More than 80 % of CPCs occur in children. Mutations in the TP53 gene is played the main role in the pathogenesis of these tumors. Choroid plexus carcinomas in 40 % of cases are associated with Li–Fraumeni syndrome. Survival rates in patients with CPC and Li–Fraumeni syndrome are extremely low. The standards of the therapy for patients with CPC are not defined. The extent of surgical resection and treatment modality correlate with prognosis. The role of adjuvant therapy in CPC remains unclear: doses and volumes of radiation therapy (RT), combinations of chemotherapeutic drugs, timing, and a combination of RT and chemotherapy (CT) have not been identified. Also, there is neither a standard CT regimen nor a prospective international study assessing the efficacy and toxicity of various combinations of cytostatics in patients with CPC. The article presents an overview of the existing molecular genetic changes, existing methods for the diagnosis and treatment of choroid plexus carcinoma.


Neurosurgery ◽  
1993 ◽  
Vol 32 (1) ◽  
pp. 131???134 ◽  
Author(s):  
Hiroshi Yuasa ◽  
Sumitaka Tokito ◽  
Masayoshi Tokunaga

Sign in / Sign up

Export Citation Format

Share Document